R R

What Is Renvela?

Renvela is a prescription phosphate binder containing sevelamer carbonate. It is used to control elevated phosphorus levels in adults and children aged six years and older with chronic kidney disease who are receiving dialysis. Renvela is available as oral tablets and powder for oral suspension. It works inside the digestive tract by binding dietary phosphate and reducing its absorption into the bloodstream. Unlike calcium-containing phosphate binders, Renvela does not supply additional calcium. It must be taken with meals and requires regular monitoring of phosphorus levels and possible gastrointestinal adverse effects.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Renvela?

Renvela is a prescription phosphate binder containing sevelamer carbonate. It is used to control elevated phosphorus levels in adults and children aged six years and older with chronic kidney disease who are receiving dialysis. Renvela is available as oral tablets and powder for oral suspension. It works inside the digestive tract by binding dietary phosphate and reducing its absorption into the bloodstream. Unlike calcium-containing phosphate binders, Renvela does not supply additional calcium. It must be taken with meals and requires regular monitoring of phosphorus levels and possible gastrointestinal adverse effects.

read more about renvela ...

Copy this HTML:

Copy HTML Copied!

How Does Renvela Work?

Renvela contains sevelamer carbonate, a nonabsorbed polymer that binds phosphate from food within the gastrointestinal tract. The bound phosphate remains in the digestive contents and is eliminated in stool rather than being absorbed into the bloodstream. This helps lower elevated serum phosphorus in patients with chronic kidney disease on dialysis. Controlling phosphorus is an important part of managing mineral balance in these patients. Renvela does not directly improve kidney filtration or remove phosphorus already circulating in the bloodstream. Its activity depends on taking each prescribed dose with food containing phosphate.

Who Can Receive Renvela Treatment?

Renvela is approved to control serum phosphorus levels in adults and children aged six years and older with chronic kidney disease who are receiving dialysis. Kidney failure can reduce the body's ability to eliminate phosphate, causing phosphorus to accumulate in the blood. Elevated phosphorus levels can contribute to complications involving bones, blood vessels, and mineral metabolism. Renvela is used alongside dietary phosphorus management and dialysis treatment. It is not approved specifically for patients with chronic kidney disease who are not receiving dialysis. Renvela is contraindicated in patients with bowel obstruction and requires caution in those with significant digestive tract disorders.

How Should Renvela Be Taken?

Renvela is taken orally three times daily with meals. Adults not already taking a phosphate binder commonly begin at 0.8 g or 1.6 g per meal, depending on their serum phosphorus concentration. Doses are adjusted according to laboratory results, usually at intervals of approximately two weeks. Tablets should be swallowed whole rather than crushed or chewed. Powder packets must be mixed with the specified amount of water or suitable food and consumed within 30 minutes. Renvela can interfere with the absorption of certain oral medications, including ciprofloxacin and mycophenolate mofetil, so separate administration or monitoring may be needed.

What Are the Side Effects and Warnings of Renvela?

Common adverse effects include nausea, vomiting, diarrhea, indigestion, abdominal pain, gas, and constipation. Serious gastrointestinal complications can include fecal impaction, bowel obstruction, ulceration, and intestinal perforation. Renvela should not be used in patients with bowel obstruction. Difficulty swallowing tablets has also been reported, particularly in patients with swallowing disorders. Because sevelamer can bind certain substances in the digestive tract, it may reduce absorption of selected medications and fat-soluble vitamins. Patients should report severe abdominal pain, persistent constipation, vomiting, or blood in the stool. Regular phosphorus monitoring helps guide treatment.

Common Questions About Renvela

Is Renvela the same as sevelamer carbonate?

Yes. Renvela is a brand name for sevelamer carbonate, a phosphate binder used in patients with chronic kidney disease on dialysis.

Why must Renvela be taken with meals?

Renvela binds phosphate from food in the digestive tract. Taking it with meals helps reduce dietary phosphorus absorption.

Can children take Renvela?

Yes. Renvela is approved for children aged six years and older with chronic kidney disease who are receiving dialysis. Pediatric doses depend on body surface area and phosphorus levels.

Can Renvela cause constipation?

Yes. Constipation is a recognized adverse effect, and serious bowel complications can occur. Persistent constipation or severe abdominal pain requires prompt medical assessment.

References

DailyMed - RENVELA (sevelamer carbonate) tablets and powder for oral suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360. Date Accessed November 3, 2026.

Renvela. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/renvela. Date Accessed November 3, 2026.

Sevelamer. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601248.html. Date Accessed November 3, 2026.

Sevelamer. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK607999/. Date Accessed November 3, 2026.

Sevelamer Carbonate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Sevelamer-Carbonate. Date Accessed November 3, 2026.